At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
ZD1839drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of ZD1839 (IRESSA®) for Patients With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction
In Brief
A Phase 2 clinical trial evaluating ZD1839 for Esophageal Cancer. Completed, enrolled 58 participants across 1 site.
Detailed Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic esophageal or gastroesophageal junction cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedDec 2005
Primary CompletionJan 2011
Study CompletionAug 2011
TodayJul 2026
First PostedDec 22, 2005
Enrollment StartOct 1, 2005
Primary CompletionJan 1, 2011
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 20.5 years ago
Interventions
ZD1839drug
ZD1839 treatment will be taken once a day PO, every day about the same time